Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534337 | 0.91 | AOC3 (0.56) | AOC3MMP2MMP3MMP9MMP8 | |
| SCHEMBL7528248 | 0.84 | AOC3 (0.46) | AOC3PTGDR2 | |
| SCHEMBL7528894 | 0.82 | AOC3 (0.46) | AOC3ALDH1A1POLB | |
| SCHEMBL7571934 | 0.81 | AOC3 (0.46) | AOC3KDM4EALDH1A1POLB | |
| SCHEMBL7527434 | 0.79 | AOC3 (0.63) | AOC3MMP2MMP3MMP9MMP8 | |
| Trifluoroacetic Acid SCHEMBL7528873 | 0.78 | AOC3 (0.52) | AOC3PTGDR2KDM4ELMNA | |
| Trifluoroacetic Acid SCHEMBL7530958 | 0.75 | AOC3 (0.40) | AOC3ALDH1A1 | |
| SCHEMBL7527633 | 0.75 | AOC3 (0.48) | AOC3PTGDR2KDM4E | |
| SCHEMBL7534329 | 0.72 | AOC3 (0.48) | AOC3ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL11490292 | 0.72 | AOC3 (0.58) | AOC3KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002038153-A1 | NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES | BIOVITRUM AB (SE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | AOC3 1/4885MMP2 675/4885MMP3 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.